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NGAL and Cardiovascular Disease in the Community March 20, 2012:1101–9Plasma Neutrophil Gelatinase–Associated Lipocalin Is Independently Associated
With Cardiovascular Disease and Mortality in Community-Dwelling Older Adults
The Rancho Bernardo Study
Objectives The purpose of this study was to determine the association between neutrophil gelatinase–associated lipocalin
(NGAL) levels and cardiovascular and all-cause mortality in community-dwelling older adults.
Background NGAL is a novel marker best known for its role in rapidly identifying acute kidney injury. Although expressed in
atherosclerosis, its association with cardiovascular disease (CVD) in the community has not been reported.
Methods We measured plasma NGAL levels in 1,393 Rancho Bernardo Study participants without CVD, mean age 70
years. Participants were followed for a mean time period of 11 years.
Results During follow-up, 436 participants died (169 from CVD). In models adjusted for traditional CVD risk factors and
creatinine clearance, NGAL was a significant predictor of CVD mortality (hazard ratio [HR] per SD log increase:
1.33, 95% confidence interval [CI]: 1.12 to 1.57), all-cause mortality (HR: 1.19, 95% CI: 1.07 to 1.32), and a
combined cardiovascular endpoint (HR: 1.26, 95% CI: 1.10 to 1.45). After further adjusting for N-terminal pro–
B-type natriuretic peptide (NT-proBNP) and C-reactive protein (CRP), NGAL remained an independent predictor of
each outcome. NGAL improved the C-statistic (0.835 to 0.842) for prediction of CVD death (p  0.001). Net re-
classification improvement (0) with the addition of NGAL was 18% (p  0.02); the integrated discrimination
index was also significant (p  0.01). Participants with NGAL and NT-proBNP above the median had increased
risk of CVD death versus those with only NT-proBNP elevated (HR: 1.43, 95% CI: 1.12 to 1.82).
Conclusions Plasma NGAL is a significant predictor of mortality and CVD in community-dwelling older adults, independent of
traditional risk factors and kidney function, and adds incremental value to NT-proBNP and CRP. The potential
impact of these results includes providing insight into new mechanisms of CVD and the possibility of improving
screening, intervention, and prevention. (J Am Coll Cardiol 2012;59:1101–9) © 2012 by the American College
of Cardiology FoundationNeutrophil gelatinase–associated lipocalin (NGAL) is a
protein belonging to the lipocalin family, and is best known
clinically as a novel and early marker of acute kidney injury
(1). NGAL is expressed by activated neutrophils and various
epithelial cells (2), and is also produced by renal tubular cells
in response to injury (1). NGAL plays a role in tumor
development (3), and may have a protective role against
bacterial infection (4), apoptosis (5), and oxidative stress (6).
Recent studies have demonstrated that NGAL is expressed
at high levels in the heart and in atherosclerotic plaques (7),
here it has been shown to inhibit the degradation of matrix
etalloproteinase-9 (8). Matrix metalloproteinase-9 is known to
play a critical role in acute coronary syndromes, serving to
weaken vessels and destabilize plaques, leading to an increased
risk of plaque rupture (9). Despite this putative role of NGAL
in atherosclerosis and acute coronary syndromes, human stud-
ies of the relationship between NGAL and cardiovascular
disease (CVD) are limited. A few small cross-sectional studies
have demonstrated increased levels of urine, serum, or plasma
NGAL among patients with heart failure (10,11), coronary
artery disease (12,13), and stroke (14,15); and 3 small obser-
vational studies in heart failure patients (n 46, n 236, and
n  186, respectively) (16–18), plus 1 in stroke patients (n 
144) (19), suggested that higher NGAL levels were associated
with increased mortality. The association between NGAL and
CVD or mortality in the general community has never been
reported. We tested the hypothesis that plasma NGAL isassociated with CVD and mortality in a population of
community-dwelling older adults.
Methods
Study population. The Rancho Bernardo Study is an ongo-
ing, prospective, population-based study of the epidemiology
of cardiovascular and other chronic diseases. Between 1972 and
1974, all adults between 30 and 80 years old who resided in
Rancho Bernardo, a community in Southern California, were
invited to participate in a study of heart disease risk factors;
5,052 (82%) enrolled. From 1992 to 1996, 1,781 of the
surviving participants attended a follow-up study visit, which
served as the baseline visit for the present analyses. Sufficient
blood was available for measurement of NGAL in 1,742
(97.8%) of the participants; the 1,393 (80.0%) who had no
history of CVD at the time of this follow-up study visit are the
focus of these analyses. Prevalent CVD at baseline was defined
as a history of physician-diagnosed myocardial infarction,
coronary revascularization, stroke, transient ischemic attack, or
peripheral arterial disease. Four participants lost to follow-up
immediately after their study visit were not included in out-
comes analyses (Fig. 1). All participants provided written
informed consent; the study protocol was approved by the
human research protection program at the University of
California, San Diego.
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March 20, 2012:1101–9 NGAL and Cardiovascular Disease in the CommunityData collection. Data collected at the 1992 to 1996 re-
search clinic visit served as the baseline for these analyses.
Medical histories and information about physical activity
(exercise 3 times per week, yes/no), alcohol consumption
(1 drinks per day vs. less or none), and current smoking
(yes/no) were obtained using standard questionnaires devel-
oped by the Rancho Bernardo Research Group. Blood
pressure, height, and weight were measured, and body mass
index (BMI; kg/m2) was calculated. Diabetes mellitus was
efined as a fasting morning plasma glucose level 126
g/dl, reported physician diagnosis, or use of diabetes-
pecific medication. Hypertension was defined as resting
lood pressure 140 mm Hg systolic or 90 mm Hg
iastolic, reported physician diagnosis, or use of antihyper-
ensive medication. Estimated creatinine clearance (CrCl)
as calculated using the Cockroft-Gault formula; results
ere not materially different after substituting the estimated
lomerular filtration rate by the Modification of Diet in
enal Disease formula instead of the CrCl, and only the
atter data are shown. Participants were followed with
eriodic clinic visits and annual mailed questionnaires
hrough July 30, 2009, an average of 11.0  3.7 years.
efinition of endpoints. The primary outcomes were
VD death, all-cause mortality, and the combined cardio-
ascular endpoint, which was defined as the first incidence
f coronary revascularization (percutaneous coronary inter-
ention or coronary artery bypass graft surgery), nonfatal
Figure 1 Flowchart of Rancho Bernardo Study Participants
Flowchart showing which Rancho Bernardo Study participants were included
in the present analyses. NGAL  neutrophil gelatinase-associated lipocalin.Myocardial infarction, or CVD
eath. Death certificates were ob-
ained for decedents and coded by a
ertified nosologist using the Inter-
ational Classification of Disease–
th Revision criteria. CVD death
ncluded deaths assigned codes
90-459.
aboratory methods. Morning
lood samples were obtained by
enipuncture after a 12-h fast.
erum and plasma were sepa-
ated, and lipids, lipoproteins,
nd glucose levels were measured
n fresh samples; the remaining
amples were stored frozen at
70°C. N-terminal pro–B-type
atriuretic peptide (NT-proBNP),
GAL, and C-reactive protein
CRP) were measured in 2009 to
010 in EDTA plasma that had
een collected at the 1992 to
996 study visit and had been
tored frozen at –70°C. NT-
roBNP was measured using the
lecsys proBNP sandwich im-
unoassay (measurable range 5
o 35,000 pg/ml; Roche Diagnostics, Indianapolis, Indiana);
of the 1,391 participants did not have sufficient plasma for
his measurement. Plasma NGAL was measured using a
creening NGAL test developed on the Luminex platform
s a competitive immunoassay (measureable range 5 to
,000 ng/ml, limit of quantification 5 ng/l; Alere Inc.,
altham, Massachusetts). Intra-assay coefficient of varia-
ion (CV) was 8%, and interassay CV was 11% at an NGAL
evel of 67 ng/ml. CRP was also measured on the Luminex
latform with a competitive immunoassay (measureable
ange 0.004 to 10.000 mg/dl; intra-assay CV 7%, interassay
V 10%).
tatistical analysis. Continuous variables are presented as
ean  SD; most laboratory values were not normally
istributed, and are presented as medians (quartile 1 to
uartile 3). Dichotomous variables are presented as percent-
ges. NGAL, NT-proBNP, and CRP were log10 trans-
ormed for incorporation in subsequent analyses.
Single-predictor associations between the clinical variables
isted in Table 1 and logNGAL levels were determined by
inear regression analysis. Backward multivariable regression
nalysis including variables with significant individual associa-
ions was used to determine which covariates were indepen-
ently associated with logNGAL levels; repeating the analysis
ith forward regression analysis yielded identical results.
Cox proportional hazards regression models were used to
etermine the association of log10NGAL with each endpoint.
issing datapoints (0.01% of data) were mean substituted.
Abbreviations
and Acronyms
BMI  body mass index
CI  confidence interval
CrCl  creatinine clearance
CRP  C-reactive protein
CV  coefficient of
variation
CVD  cardiovascular
disease
HDL  high-density
lipoprotein
HR  hazard ratio
IDI  integrated
discrimination improvement
NGAL  neutrophil
gelatinase–associated
lipocalin
NRI  net reclassification
improvement
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
ROC  receiver-operating
characteristicodel 1 adjusted for age and sex. Model 2 additionally
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NGAL and Cardiovascular Disease in the Community March 20, 2012:1101–9adjusted for traditional cardiovascular risk factors, including
categorically defined diabetes, hypertension, and current smok-
ing, plus continuously defined systolic blood pressure, total
cholesterol, high-density lipoprotein (HDL), kidney function,
and BMI. Model 3 additionally adjusted for logNT-proNBP
and logCRP. Analyses were also performed with NGAL as a
binary variable (above or below the median), and Kaplan-
Meier cumulative survival plots were constructed with log-rank
tests used to compare groups. To help understand to what
extent NGAL levels reflect kidney function as opposed to
other, unmeasured factors, an additional exploratory analysis
was performed; this model evaluated the other covariates from
Model 3 but without logNGAL. We tested for interactions
between logNGAL levels and both sex and diabetes using Cox
proportional hazards models with interaction terms, and by
performing sex- and diabetes-stratified analyses.
In fully adjusted analyses, both logNGAL and logNT-
proBNP were independent predictors of each outcome, but
logCRP was not. Therefore, to further understand the incre-
mental benefit of NGAL when combined with NT-proBNP
levels, we divided participants into 4 groups on the basis of
whether their levels were above or below the median for each
of these 2 biomarkers. Kaplan-Meier cumulative survival plots
Baseline Characteristics of the Study PopulationTable 1 Baseline Characteristics of the Study Population
Age, yrs 70 11
Male 35.8
Vital signs
Heart rate, beats/min 65 11
Systolic BP, mm Hg 135 22
Diastolic BP, mm Hg 76 9
Cardiovascular risk factors
Hypertension 49.0
Current smoking 7.7
Ever smoked 55.1
Diabetes 12.4
Medication use
Aspirin 26.1
Lipid-lowering 9.6
Nutrition and activity
Body mass index, kg/m2 25.5 4.0
Waist-hip ratio, cm/cm 0.83 0.09
Exercise  3/week 71.0
Alcohol  3/week 45.2
Laboratory values
NT-proBNP, pg/ml 112 (56–211)
CRP, mg/dl 0.78 (0.37–1.71)
Fasting glucose, mg/dl 94 (88–100)
CrCl, ml/min 62 (48–79)
Total cholesterol, mg/dl 209 (187–234)
Triglycerides, mg/dl 103 (74–146)
HDL, mg/dl 57 (46–70)
LDL, mg/dl 127 (106–148)
Values are mean  SD, %, or median (quartile 1–quartile 3).
BP blood pressure; CrCl creatinine clearance; CRP C-reactive protein; HDL high-density
lipoprotein; LDL low-density lipoprotein; NT-proBNP N-terminal pro–B-type natriuretic peptide.were again constructed, and groups compared using the log-rank test. We tested for an interaction between NGAL group
and NT-proBNP group using Cox proportional hazards mod-
els. Cox models were also used to compare groups after
adjusting for traditional CVD risk factors, CrCl, and BMI.
Receiver-operating characteristic (ROC) curves were con-
structed and areas under the ROC curves (C-statistic) were
calculated using a method adapted for survival models (20), to
evaluate the incremental improvement in discrimination with
logNGAL, for each outcome. LogNGAL was added to 2
separate models: first, to the baseline model including the
covariates from Model 2 (traditional CVD risk factors plus
CrCl and BMI), and second to the Model 3 covariates (which
also included logNT-proBNP and logCRP). Cox model in-
crement tests were used to assess whether global model fit
improved with the addition of logNGAL. For comparison, the
C-statistics were also evaluated for the addition of NT-
proBNP and of CRP to Model 2.
Model calibration was assessed using a Hosmer-
Lemeshow test modified for use with Cox proportional
hazards models (21). Integrated discrimination improve-
ment (IDI) and net reclassification improvement (NRI) for
the addition of logNGAL to Model 2 were calculated
according to the methods of Pencina et al. (22). Because
NRI calculations are highly sensitive to chosen cut-points,
and because there are no pre-specified cut-points for long-
term follow-up in elderly individuals with these specific
outcomes, the category-free NRI (NRI 0) was utilized.
The NRI 0 also facilitates comparison with other studies.
Both the “event NRI” and the “nonevent NRI” were also
calculated (23). The event NRI is the amount of correct
reclassification that occurred among participants who had
events, while the nonevent NRI is the amount of correct
reclassification among participants who did not have events.
For reclassification analyses, we estimated risk at 12 years.
A 2-tailed p  0.05 was considered statistically significant.
Data were analyzed using SPSS version 19.0 (Chicago, Illinois).
Results
Baseline characteristics. The mean age of the overall study
population (n  1,742) at baseline was 71  11 years. The
median NGAL level was 200 ng/ml (150 to 287 ng/ml) and
was slightly higher among the 349 participants with prev-
alent CVD (median 246 ng/ml [172 to 348 ng/ml]).
Subsequent analyses were performed only on the subset
comprising the 1,393 participants who were free of known
CVD at baseline. Baseline characteristics of the study
population are shown in Table 1. In this group, the mean
age at baseline was 70  11 years and 36% were men. The
median NGAL level was 192 ng/ml (146 to 270 ng/ml) and
was similar in both sexes (199 ng/ml in men vs. 189 ng/ml
in women, p  0.14). The 95% range of NGAL concen-
trations was from 71 to 610 ng/ml.
Correlates of NGAL levels. Correlations between various
demographic, clinical, and laboratory variables and NGAL
levels are shown in Table 2. The strongest individual correla-
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March 20, 2012:1101–9 NGAL and Cardiovascular Disease in the Communitytions were with higher CRP, older age, lower CrCl, and higher
NT-proBNP levels. Weaker associations were seen with in-
creased systolic blood pressure, lower total and HDL choles-
terol, hypertension, diabetes, and relative abstinence from
alcohol. Higher heart rate, fasting glucose level, and lower
Individual and MultivariableCovariates of logNGAL Lev lsTable 2 Individual and MultivariableCovariates of logNGAL Levels
Individual Multivariable*
r p Value  p Value
Demographics
Age 0.22 0.001
Male 0.04 NS
Vital signs
Heart rate 0.05 0.04
Systolic BP 0.12 0.001
Diastolic BP 0.02 NS
Cardiovascular risk factors
Hypertension 0.08 0.01
Current smoking 0.004 NS
Diabetes 0.05 0.04
Nutrition and activity
Waist-hip ratio 0.04 NS
Body mass index 0.01 NS
Exercise 3/week 0.00 N/S
Alcohol 3 drinks/week –0.06 0.03
Medications
Aspirin 0.003 NS
Lipid-lowering 0.001 NS
Laboratory values
log NT-proBNP 0.19 0.001
log CRP 0.35 0.001 0.34 0.001
log Fasting glucose 0.05 0.04
log CrCl –0.22 0.001 –0.24 0.001
log Triglycerides –0.05 NS
log Total cholesterol –0.07 0.01
log HDL –0.07 0.01 –0.11 0.001
log LDL –0.01 NS
*R2  0.18.
NGAL  neutrophil gelatinase–associated lipocalin; other abbreviations as in Table 1.
Multivariable Cox Proportional Hazards Models for Risk of Death orper 1 SD Increase in log10NGAL nd Other Bioma kerTable 3 Multiva iable Cox Proportional Hazards Models for Risper 1 SD Increase in log10NGAL and Other Biomarkers
Cardiovascular Mortality
HR (95% CI) p Value
Number of deaths/events 169
Unadjusted 1.72 (1.47–2.01)† 0.001
Model 1 1.34 (1.15–1.58)† 0.001
Model 2 1.33 (1.12–1.57)‡ 0.001
Model 3
NGAL 1.25 (1.05–1.48) 0.01
NT-proBNP 1.80 (1.48–2.18)† 0.001
CRP 1.09 (0.90–1.31) 0.38
Model 1 was adjusted for age and sex. Model 2 was adjusted for Model 1  diabetes, hyperten
creatinine clearance, and body mass index. Model 3 was adjusted for Model 2  log10NT-proBNP
revascularization, myocardial infarction, or CVD death. †Values are significant at p  0.001. ‡ValCI  confidence interval; CRP  C-reactive protein; CVD  cardiovascular disease; HDL  high-density
N-terminal pro–B-type natriuretic peptide.triglyceride levels were also weakly associated with higher
NGAL levels. NGAL levels were not significantly associated
with BMI, smoking status, frequent exercise, or use of lipid-
lowering medications.
Three variables were independently associated with
higher NGAL levels in multivariable analysis: CRP, lower
CrCl, and lower HDL cholesterol levels. The adjusted R2
value of this model was 0.18 with identical results whether
forward or backward selection was used.
NGAL levels and outcomes. Participants were followed
for a mean of 11.0  3.7 years (maximum 16.2 years), during
which time there were 436 deaths (31%), including 169 (39%)
that were due to cardiovascular causes. There were 101 partic-
ipants who suffered a fatal or nonfatal myocardial infarction
during follow-up, and 75 who had coronary revascularization
(25 of whom also had a myocardial infarction). As these events
were not mutually exclusive, 254 participants experienced a first
CVD event when defined as the composite of MI, revascular-
ization, or CVD death.
Multivariable Cox proportional hazards models were used to
evaluate the adjusted risk of death per each 1 SD increase in
log10NGAL level (Table 3). After adjusting for age and sex
(Model 1), the hazard ratio (HR) for CVD death per 1 SD
increase in NGAL was 1.34 (95% confidence interval [CI]:
1.15 to 1.58, p 0.001). The risk estimate was only minimally
attenuated after further adjusting for traditional CVD risk
factors, kidney function, and BMI (Model 2). In unadjusted
and adjusted models, log10NGAL levels were also associated
ith all-cause mortality (Model 2 HR: 1.19, 95% CI: 1.07 to
.32, p 0.001) and the combined cardiovascular outcome of
oronary revascularization, myocardial infarction, or CVD
eath (Model 2 HR: 1.26, 95% CI: 1.10 to 1.45, p  0.001).
As a sensitivity analysis, we also evaluated NGAL as a
inary variable with participants grouped on the basis of an
GAL level above or below the median (192 ng/ml) (Fig. 2).
djusted Cox proportional hazards models for each end-
oint were again performed, and results did not materially
iffer (Online Table 1).
eath or CVD
All-Cause Mortality Combined Cardiovascular Endpoint*
R (95% CI) p Value HR (95% CI) p Value
436 254
(1.34–1.64)† 0.001 1.48 (1.30–1.69)† 0.001
(1.10–1.35)† 0.001 1.29 (1.13–1.47)† 0.001
(1.07–1.32)‡ 0.001 1.26 (1.10–1.45)‡ 0.001
(1.03–1.28) 0.02 1.21 (1.05–1.39) 0.01
(1.26–1.61)† 0.001 1.52 (1.29–1.79)† 0.001
(0.95–1.19) 0.29 1.08 (0.93–1.26) 0.31
nd current smoking (dichotomous variables) and systolic blood pressure, total cholesterol, HDL,
g10CRP. Bold values are significant at p  0.05. *Combined Cardiovascular Endpoint is coronary
significant at p  0.01.CVDk of
H
1.48
1.22
1.19
1.14
1.42
1.06
sion, a
and lo
ues arelipoprotein; HR  hazard ratio; NGAL  neutrophil gelatinase–associated lipocalin; NTproBNP 
b
i
a
t
s
t
n
p
N
e
T
a
i
i
a
p
N
o
N
0
p
0
(
o
1
1
D
R
i
i
a
r
(
s
A
a
i
1106 Daniels et al. JACC Vol. 59, No. 12, 2012
NGAL and Cardiovascular Disease in the Community March 20, 2012:1101–9To explore the pathophysiology behind the robust asso-
ciations of NGAL with long-term CVD and mortality, we
next sought to determine whether NGAL was acting as a
surrogate (but superior) marker of either kidney function or
inflammation. An exploratory analysis was performed with
NGAL excluded from Model 3, to determine whether CrCl
or CRP would manifest significant associations in the
absence of NGAL. Neither CrCl nor CRP was indepen-
dently predictive for any of the 3 endpoints.
We also tested for interactions between logNGAL levels
and sex or diabetes in prediction of any of the 3 outcomes;
none was significant (p interaction all 0.17).
Combinations of markers. To investigate whether NGAL
adds information that is complementary to NT-proBNP
and CRP, 2 markers frequently measured for assessing
prognosis in this and other settings, we further adjusted the
Cox proportional hazards models for these 2 biomarkers
(Model 3, Table 3 and Online Table 1). After adjusting,
oth logNGAL and logNT-proBNP, but not logCRP, were
ndependently associated with CVD death, all-cause mortality,
nd the combined cardiovascular endpoint. To further inves-
igate the interplay between NGAL and NT-proBNP, we
tratified participants into 4 groups on the basis of whether
heir level of each marker was above or below the median (192
g/ml for NGAL and 111 pg/ml for NT-proBNP). Partici-
ants with levels above the median for both NGAL and
T-proBNP had a significantly higher incidence of all 3
ndpoints, compared with each of the other 3 groups (Fig. 3).
here was a borderline significant interaction between NGAL
nd NT-proBNP for prediction of all-cause mortality (p for
nteraction  0.11) and the composite cardiac endpoint (p for
nteraction  0.10), with NGAL levels showing a stronger
ssociation with outcomes among individuals whose NT-
roBNP level was also elevated above the median.
In adjusted analyses, individuals with both NGAL and
T-proBNP levels above the median had an increased risk
f CVD death compared with those with only elevated
GAL (adjusted HR: 1.59, 95% CI: 1.18 to 2.16, p 
.01), and compared with those with only elevated NT-
roBNP (adjusted HR: 1.43, 95% CI: 1.12 to 1.82, p 
.01). They also had an increased risk of all-cause mortality
adjusted HR: 1.49, 95% CI: 1.20 to 1.84, p  0.001) and
f the combined cardiovascular endpoint (adjusted HR:
.65, 95% CI: 1.24 to 2.20) compared with those with only
marker elevated.
iscrimination and reclassification. The area under the
OC curve (C-statistic) for prediction of CVD death
mproved from 0.835 to 0.842, with a highly significant
ncrement test in the Cox model (p  0.001), with the
ddition of NGAL to a model adjusted for traditional CVD
isk factors, kidney function, and BMI (Model 2)
Online Table 2). For comparison, the C-statistics are also
hown for the addition of NT-proBNP and for CRP.
dding NGAL to the model that included NT-proBNP
nd CRP in addition to the risk factors (Model 3) alsoFigure 2 NGAL Level and Risk of Death or CVD
Kaplan-Meier cumulative survival curves on the basis of neutrophil gelatinase–
associated lipocalin (NGAL) levels above or below the median (192 ng/ml).
Among participants with NGAL levels below the median there were 161 deaths
(55 cardiovascular) and 94 instances of the combined endpoints; among those
with NGAL levels above the median there were 275 deaths (114 cardiovascu-
lar) and 160 instances of the combined endpoint. (A) Cardiovascular disease
(CVD) death. (B) All-cause mortality. (C) Combined cardiovascular endpoint
(coronary revascularization, myocardial infarction, or CVD death).mproved the C-statistic, from 0.851 to 0.855 (p  0.01).
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March 20, 2012:1101–9 NGAL and Cardiovascular Disease in the CommunityImprovements in the C-statistic for prediction of all-cause
mortality were more modest but still significant. For
all-cause mortality, the addition of NGAL to Model 2
resulted in a small increase in the C-statistic from 0.801
to 0.803 (p  0.001). It increased further from 0.806 to
0.808 (p  0.02) with the addition of NGAL to Model 3
(including NT-proBNP and CRP). The largest improve-
ments in the C-statistic came with the use of NGAL for
prediction of the combined cardiovascular endpoint, above
and beyond both the risk factor model (Model 2), and the
model with the other 2 biomarkers (Model 3).
Assessment with the Hosmer-Lemeshow test indicated good
calibration for the addition of NGAL to the adjusted Model 2, for
each of the 3 outcomes (p  0.22 for each). The IDI was also
significant for the addition of NGAL to Model 2, for each of the
3 outcomes (IDI for CVD death 0.008, p 0.01; for all-cause
mortality  0.005, p  0.002; and for the combined cardiovas-
cular endpoint  0.009, p  0.009).
We assessed reclassification using the category-free NRI
(NRI 0). The addition of NGAL to Model 2 resulted in a
significant improvement in the NRI (0) of 18.0% (p 0.02)
for the CVD death endpoint. This was the result of both
correct upward reclassification of those with events (net gain in
reclassification of 11.2%), and from correct downward reclas-
sification of nonevents (net gain in reclassification of 6.9%).
For all-cause mortality the NRI (0) was 12.8% (p  0.02)
(event NRI  4.4%, nonevent NRI  8.4%), and for the
combined coronary endpoint the NRI (0) was 25.3% (p 
0.001) (event NRI  14.3%, nonevent NRI  11.1%). For
comparison, the IDI and NRI (0) for the addition of
NT-proBNP or CRP to Model 2 are shown in Online Table 3.
Discussion
Our study demonstrates that higher levels of plasma NGAL are
independently associated with an increased risk of CVD death,
all-cause mortality, and the combined endpoint of coronary
revascularization, nonfatal myocardial infarction, or CVD death,
in a cohort of older community-dwelling adults with no anteced-
ent clinical CVD. We also provide novel evidence that NGAL
adds significantly to the predictive value of NT-proBNP and
CRP in this setting. Finally, to our knowledge, this is the first
study of community-dwelling individuals to report the clinical
factors associated with NGAL levels, and the first longitudinal
community-based study to report the prognostic value of NGAL
levels.
Our findings suggest that plasma NGAL adds complementary
information to established risk factors and biomarkers, includ-
ing NT-proBNP and CRP. Although NGAL is known by
many as a marker of acute renal injury, our results suggest that
plasma NGAL provides important prognostic information and
is not merely serving as a surrogate measure of renal function:
in fact, correlation between NGAL and CrCl was quite
modest (r  –0.22). In addition, CrCl was not predictive of
any of the 3 outcomes, even after NGAL was removed fromFigure 3 Combination of NGAL and NT-proBNP and Risk of
Death or CVD
Kaplan-Meier curves on the basis of NGAL and N-terminal pro–B-type natriuretic
peptide (NT-proBNP) levels above or below the median (192 ng/ml for NGAL
and 111 pg/ml for NT-proBNP). Four groups are compared: those with both
NGAL and NT-proBNP below the median (n  380; 57 deaths, 12 cardiovascu-
lar; 38 combined endpoint occurrences), those with only NGAL above the
median (n  316; 67 deaths, 20 cardiovascular; 40 combined endpoint occur-
rences), those with only NT-proBNP above the median (n  316; 104 deaths,
43 cardiovascular; 56 combined endpoint occurrences), and those with both
markers above the median (n  378; 207 deaths, 93 cardiovascular; 119
combined endpoint occurrences). Three participants did not have NT-proBNP
measured. Log-rank p value 0.001 for each. (A) CVD death. (B) All-cause
mortality. (C) Combined cardiovascular endpoint (coronary revascularization,
myocardial infarction, or CVD death). Abbreviations as in Figure 2.the models. These findings demonstrate clearly that plasma
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NGAL and Cardiovascular Disease in the Community March 20, 2012:1101–9NGAL is providing prognostic information that is indepen-
dent of glomerular filtration rate.
NGAL was weakly associated with several traditional CVD
risk factors, including age, systolic blood pressure, hyperten-
sion, and diabetes. This is consistent with findings in a
previous small study of 156 subjects with asymptomatic carotid
plaque, in whom plasma NGAL levels were associated with
age, blood pressure, and a history of hypertension (24). How-
ever, in the present study, none of these factors remained
significantly associated with NGAL levels after taking into
account other variables including CRP levels, kidney function,
and cholesterol levels. Furthermore, the association between
NGAL and outcomes was independent of these risk factors.
CRP levels showed the strongest association with NGAL
levels (r  0.35); however, NGAL remained associated with
ortality and CVD even after adjusting for CRP levels. In fact,
RP was not a significant predictor of any of the 3 outcomes
tudied, after adjusting for traditional CVD risk factors,
GAL, and NT-proBNP. To assess the possibility that
GAL and CRP were providing overlapping information, we
emoved NGAL from the models. Even with NGAL removed
rom the models, CRP was not a significant predictor of
utcomes in adjusted models. Thus, despite the modest cor-
elation between NGAL and CRP, our findings suggest that
GAL is reflecting a pathophysiology distinct from CRP.
We also found a weak but significant correlation between
GAL and NT-proBNP levels (r  0.19). This is remark-
ably similar to the correlation reported by Yndestad et al.
(17) in the much smaller study of serum NGAL in a
subgroup of 236 acute heart failure patients from the
OPTIMAAL (OPtimal Trial In Myocardial infarction with
Angiotensin II Antagonist Losartan) trial (r  0.15). In the
present study, both NGAL and NT-proBNP levels were
each associated with CVD death, all-cause mortality, and
the combined cardiovascular outcome independent of one
another. The 2 markers added complementary information,
with by far the poorest outcomes seen in individuals with
elevated levels of both biomarkers. This finding is in
accordance with our current understanding of the distinct
biologic pathways leading to expression of natriuretic pep-
tides versus plasma NGAL. While natriuretic peptides are
expressed primarily in the setting of myocardial strain (25),
NGAL expression, though not fully delineated, is believed
to be up-regulated in settings of vascular damage and
remodeling, and atherosclerosis, among others (26).
Animal models have demonstrated that NGAL is hyperex-
pressed in the myocardium following myocardial infarction
(7,17). Its colocalization with matrix metalloproteinase-9 (7)
nd its ability to enhance the proteolytic activity of matrix
etalloproteinase-9 (8) suggest that NGAL may be an active
ediator of acute coronary syndromes and their negative
equelae, rather than a passive bystander. This potential role in
he pathogenesis of CVD is 1 characteristic that may ultimately
istinguish plasma NGAL from NGAL expressed in the
rine, as well as from the host of other candidate biomarkers
ying for recognition in the burgeoning field of CVD risk rtratification. Irrespective of biology, NGAL may be a good
andidate for risk assessment because it improves both the
-statistic and the NRI.
Several other features of NGAL also help to distinguish it
rom other novel CVD biomarkers. Unlike natriuretic peptides
nd other markers, NGAL levels are not greatly affected by
MI, age, or sex. The predictive ability of NGAL appears to
e independent of traditional CVD risk factors, kidney func-
ion, and other markers, and NGAL was similarly predictive in
oth sexes. It improved both reclassification and discrimina-
ion, and a single baseline value was predictive of risk even a
ecade later. These favorable characteristics of NGAL improve
he likelihood that it will ultimately prove to be a clinically
seful tool for CVD risk stratification.
Morrow and de Lemos (27) have proposed 3 criteria for
valuating novel biomarkers, including whether the marker is
asy to measure and accurate, whether the marker adds new
nformation, and whether the marker will improve clinical
anagement. Our findings in the present study support, in
art, an affirmative answer to the first 2 criteria. Although
hether NGAL will improve clinical management must await
urther studies, the biology underlying the expression of this
ovel marker provides cause for optimism in this regard.
ecause of its possible causal and distinct role in acute coronary
yndromes, NGAL may prove to be a suitable target for
harmacologic intervention, and with further study, measure-
ent of NGAL levels may help to better match individuals
ith appropriate therapies.
tudy strengths and limitations. Strengths of this study
nclude the well-characterized, population-based sample of
lder adults, and the long-term follow-up. A significant limi-
ation is the relative homogeneity of the cohort. Because the
ancho Bernardo Study population is largely white and middle
o upper-middle class, these results may not be generalizable to
ther populations. However, in one regard, the homogeneity
an be viewed as a strength to the extent that it limits
onfounding by socioeconomic status and access to health care.
Though significant, the absolute improvement in the
-statistic with NGAL was small, and the clinical utility of
GAL, if any, remains to be seen. Because no measures of
lbuminuria were included in the analysis, one cannot
ssume the observed relationships were completely indepen-
ent of kidney disease, although they were independent of
enal function as assessed by estimated CrCl.
Another limitation is the long-term storage of blood sam-
les, which could raise questions about the stability of the
nalyte. Before measurement of NGAL levels, blood samples
ere stored, frozen at –70°C, for 14 to 18 years. Although the
ong-term stability of plasma NGAL is difficult to directly
ssess, the fact that NGAL levels showed strong associations
ith clinical outcomes argues that there is sufficient stability to
reserve a clinical signal. It is unlikely that antigen would decay
ifferentially on the basis of different participant long-term
utcomes, thereby creating a clinical signal where there was not
ne originally. However, the question of stability could still
aise concerns of whether the particular median values identi-
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March 20, 2012:1101–9 NGAL and Cardiovascular Disease in the Communityfied would be the same in fresher samples. If some decay had
occurred, this would lower the specific values identified in our
study. NGAL was measured at 1 point in time. Future studies
should evaluate whether serial measurement of NGAL might
provide more specific information on risk of CVD events
above and beyond the level at 1 point in time at baseline.
Finally, the screening NGAL assay utilized for this study was
not calibrated to the commercially available Alere Triage
NGAL Test and is known to give different values (28).
Conclusions
NGAL levels are independently associated with increased risk of
CVD mortality, all-cause mortality, and cardiovascular disease
during long-term follow-up of community-dwelling older adults
free from prior CVD. Plasma NGAL provides information that is
complementary to traditional CVD risk factors, NT-proBNP,
and CRP. The potential impact of these results, if confirmed and
expanded upon in future studies, includes providing insight into
new mechanisms of CVD and the possibility of improving
screening, intervention, and prevention.
Reprint requests and correspondence: Dr. Lori B. Daniels,
UCSD Division of Cardiology, Mail Code 7411, 9444 Medical
Center Drive, La Jolla, California 92037-7411. E-mail:
lbdaniels@ucsd.edu.
REFERENCES
1. Devarajan P. NGAL in acute kidney injury: from serendipity to utility.
Am J Kidney Dis 2008;52:395–9.
2. Friedl A, Stoesz SP, Buckley P, Gould MN. Neutrophil gelatinase-
associated lipocalin in normal and neoplastic human tissues. Cell
type-specific pattern of expression. Histochem J 1999;31:433–41.
3. Bolignano D, Donato V, Lacquaniti A, et al. Neutrophil gelatinase-
associated lipocalin (NGAL) in human neoplasias: a new protein
enters the scene. Cancer Lett 2010;288:10–6.
4. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN,
Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent
that interferes with siderophore-mediated iron acquisition. Mol Cell
2002;10:1033–43.
5. Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, Kehrer JP.
Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem
J 2005;391:441–8.
6. Roudkenar MH, Halabian R, Ghasemipour Z, et al. Neutrophil
gelatinase-associated lipocalin acts as a protective factor against
H(2)O(2) toxicity. Arch Med Res 2008;39:560–6.
7. Hemdahl AL, Gabrielsen A, Zhu C, et al. Expression of neutrophil
gelatinase-associated lipocalin in atherosclerosis and myocardial in-
farction. Arterioscler Thromb Vasc Biol 2006;26:136–42.
8. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular
weight urinary matrix metalloproteinase (MMP) activity is a complex
of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin
(NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem
2001;276:37258–65.
9. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and
atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251–62.
10. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL.of tubular damage, is increased in patients with chronic heart failure.
Eur J Heart Fail 2008;10:997–1000.
1. Poniatowski B, Malyszko J, Bachorzewska-Gajewska H, Malyszko JS,
Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a
marker of renal function in patients with chronic heart failure and
coronary artery disease. Kidney Blood Press Res 2009;32:77–80.
2. Choi KM, Lee JS, Kim EJ, et al. Implication of lipocalin-2 and visfatin
levels in patients with coronary heart disease. Eur J Endocrinol
2008;158:203–7.
3. Zografos T, Haliassos A, Korovesis S, Giazitzoglou E, Voridis E, Katritsis D.
Association of neutrophil gelatinase-associated lipocalin with the severity of
coronary artery disease. Am J Cardiol 2009;104:917–20.
4. Elneihoum AM, Falke P, Axelsson L, Lundberg E, Lindgarde F,
Ohlsson K. Leukocyte activation detected by increased plasma levels of
inflammatory mediators in patients with ischemic cerebrovascular
diseases. Stroke 1996;27:1734–8.
5. Anwaar I, Gottsater A, Ohlsson K, Mattiasson I, Lindgarde F.
Increasing levels of leukocyte-derived inflammatory mediators in
plasma and cAMP in platelets during follow-up after acute cerebral
ischemia. Cerebrovasc Dis 1998;8:310–7.
6. Bolignano D, Basile G, Parisi P, Coppolino G, Nicocia G, Buemi M.
Increased plasma neutrophil gelatinase-associated lipocalin levels pre-
dict mortality in elderly patients with chronic heart failure. Rejuvena-
tion Res 2009;12:7–14.
7. Yndestad A, Landro L, Ueland T, et al. Increased systemic and
myocardial expression of neutrophil gelatinase-associated lipocalin in
clinical and experimental heart failure. Eur Heart J 2009;30:1229–36.
8. Maisel AS, Mueller C, Fitzgerald R, et al. Prognostic utility of plasma
neutrophil gelatinase-associated lipocalin in patients with acute heart
failure: The NGAL EvaLuation Along with B-type NaTriuretic
Peptide in acutely decompensated heart failure (GALLANT) trial.
Eur J Heart Fail 2011;13:846–51.
9. Falke P, Elneihoum AM, Ohlsson K. Leukocyte activation: relation to
cardiovascular mortality after cerebrovascular ischemia. Cerebrovasc
Dis 2000;10:97–101.
0. Kremers WK. Concordance for Survival Time Data: Fixed and Time-
Dependent Covariates and Possible Ties in Predictor and Time. Tech-
nical Report Series #80. Rochester, MN: Mayo Clinic, 2007:1–17.
1. May S, Hosmer DW. A simplified method of calculating an overall
goodness-of-fit test for the Cox proportional hazards model. Lifetime
Data Anal 1998;4:109–20.
2. Pencina MJ, D’Agostino RB Sr., D’Agostino RB Jr., Vasan RS.
Evaluating the added predictive ability of a new marker: from area
under the ROC curve to reclassification and beyond. Stat Med
2008;27:157–72, discussion 207–12.
3. Pencina MJ, D’Agostino RB Sr., Steyerberg EW. Extensions of net
reclassification improvement calculations to measure usefulness of new
biomarkers. Stat Med 2011;30:11–21.
4. Elneihoum AM, Falke P, Hedblad B, Lindgarde F, Ohlsson K.
Leukocyte activation in atherosclerosis: correlation with risk factors.
Atherosclerosis 1997;131:79–84.
5. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol
2007;50:2357–68.
6. Bolignano D, Coppolino G, Lacquaniti A, Buemi M. From kidney to
cardiovascular diseases: NGAL as a biomarker beyond the confines of
nephrology. Eur J Clin Invest 2010;40:273–6.
7. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel
cardiovascular biomarkers. Circulation 2007;115:949–52.
8. Triage NGAL [package insert]. San Diego, CA: Inverness Medical;
2009.
Key Words: biomarkers y cardiovascular disease y elderly y natriuretic
peptides y risk factors.
APPENDIXUrinary neutrophil gelatinase associated lipocalin (NGAL), a marker For expanded tables, please see the online version of this paper.
Go to http://cme.jaccjournals.org
to take the CME quiz for this article.
